4.3 Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol
Key Takeaways
- Vagal maneuvers, particularly the modified Valsalva maneuver, are first-line non-pharmacological therapy for stable regular narrow-complex SVT.
- If vagal maneuvers fail, administer Adenosine as a 6 mg rapid IV push immediately followed by a 20 mL saline flush and extremity elevation.
- If SVT does not convert within 1 to 2 minutes, administer a second dose of 12 mg Adenosine rapid IV push with flush.
- Adenosine's extremely short half-life (<10 seconds) mandates rapid IV push and immediate flushing.
- Patients must be warned of transient side effects including chest pressure, flushing, dyspnea, and a brief period of asystole.
Stable Narrow-Complex Tachycardia: Vagal Maneuvers & Adenosine Protocol
When the initial assessment determines that a patient with a tachyarrhythmia is hemodynamically stable (lacking hypotension, altered mental status, signs of shock, ischemic chest pain, or acute heart failure), the urgency shifts from immediate electrical intervention to a deliberate, pharmacological approach.
If the subsequent ECG analysis reveals a regular, narrow QRS complex (<0.12 seconds), the diagnosis is most likely Supraventricular Tachycardia (SVT). The management of stable SVT follows a stepwise progression, beginning with simple physical maneuvers and advancing to specific antiarrhythmic medications, primarily adenosine.
First-Line Therapy: Vagal Maneuvers
Vagal maneuvers are the initial intervention of choice for terminating stable SVT. These physical actions stimulate the vagus nerve (cranial nerve X), which is a major component of the parasympathetic nervous system. Vagal stimulation releases acetylcholine at the atrioventricular (AV) node, temporarily slowing conduction and increasing the refractory period. Because many SVTs (like AV nodal reentrant tachycardia) rely on the AV node to maintain their circuit, this brief block can successfully break the tachycardia and allow the normal sinus node to resume control.
Types of Vagal Maneuvers
- Valsalva Maneuver: This is the most common and often most effective method. The patient is instructed to forcibly exhale against a closed glottis, essentially bearing down as if having a bowel movement. A standardized way to achieve this is asking the patient to blow into a 10cc syringe forcefully enough to push the plunger back, maintaining the pressure for 10 to 15 seconds.
- Modified Valsalva Maneuver: Recent studies, such as the REVERT trial, have shown that modifying the standard Valsalva significantly increases its success rate.
- Technique: The patient performs the standard Valsalva strain (blowing into a syringe) for 15 seconds while seated semi-recumbent. Immediately after the strain, the patient is laid flat (supine), and their legs are passively raised to a 45-degree angle by a provider for 15 seconds. This position change rapidly increases venous return to the heart, maximizing vagal tone and improving conversion rates.
- Carotid Sinus Massage: This involves applying firm, circular pressure to the carotid sinus (located just below the angle of the jaw) for 5 to 10 seconds. Important Caveats: This should only be performed by a physician. It is contraindicated in patients with known carotid bruits, a history of transient ischemic attacks (TIAs), or stroke, due to the risk of dislodging an atherosclerotic plaque.
Providers should continuously monitor the ECG during vagal maneuvers. If the rhythm successfully converts to normal sinus rhythm, further interventions are unnecessary, though the patient should remain under observation.
The Adenosine Protocol
If vagal maneuvers are unsuccessful, the next step in the algorithm is the administration of adenosine. Adenosine is a unique antiarrhythmic agent; it is an endogenous purine nucleoside that acts primarily on the AV node.
Mechanism of Action
Adenosine causes profound, temporary AV nodal blockade. By briefly halting electrical conduction through the AV node, it effectively "resets" the electrical system, interrupting the reentrant circuits that drive SVT.
Crucial Pharmacokinetics: The Need for Speed
The most important characteristic of adenosine is its incredibly short half-life—typically less than 10 seconds in the blood. It is rapidly metabolized by enzymes in the red blood cells and endothelial cells.
Because it degrades so quickly, the method of administration is critical. If given slowly, it will be destroyed before it ever reaches the heart, rendering it entirely ineffective. Therefore, the "Rapid IV Push" technique is mandatory.
Standard Dosing and Administration Protocol
-
Preparation:
- Ensure the patient is on a continuous cardiac monitor, and a defibrillator is immediately available in the room.
- Establish reliable IV access, preferably in a large proximal vein (e.g., the antecubital fossa). A central line is not required but necessitates lower doses if present.
- Draw up the adenosine and a separate 20 mL syringe of normal saline flush.
- Ideally, use a stopcock or a Y-connector on the IV line to allow immediate flushing.
-
First Dose:
- Administer 6 mg of Adenosine as a very rapid IV push (over 1 to 3 seconds).
- Immediate Flush: Immediately follow the adenosine with a rapid 20 mL normal saline flush.
- Elevation: Immediately elevate the extremity with the IV access for 10-20 seconds to utilize gravity to facilitate rapid delivery to the central circulation.
-
Assessment and Second Dose:
- Observe the monitor continuously.
- If the SVT does not convert within 1 to 2 minutes after the first dose, prepare the second dose.
- Administer 12 mg of Adenosine using the exact same rapid push, flush, and elevate technique.
Expected Side Effects and Patient Preparation
Before administering adenosine, it is crucial to warn the patient about its effects. Because adenosine causes temporary AV block, it frequently produces a brief period of asystole (a flatline on the ECG) lasting for a few seconds before the sinus node takes over.
This brief cessation of cardiac activity, along with the drug's vasodilatory properties, causes intense, though transient, side effects. Patients often report:
- A sudden sense of impending doom or extreme anxiety.
- Intense chest pressure or heaviness.
- Flushing of the face and neck.
- Dyspnea or shortness of breath.
Providers must reassure the patient that these sensations are normal, expected, and will resolve completely within seconds as the drug rapidly metabolizes.
What is the recommended first-line non-pharmacological intervention for a hemodynamically stable patient presenting with regular narrow-complex supraventricular tachycardia (SVT)?
Which of the following options correctly describes the administration protocol for the initial dose of IV Adenosine in stable SVT?
If a stable regular narrow-complex SVT fails to convert after the initial 6 mg dose of Adenosine, what is the recommended second dose?
Prior to administering Adenosine, what transient physiological response and patient sensation should the provider warn the patient about?